Chairs: Daphne Haas-Kogan, MD, and Michael Lim, MD
SNO is pleased to share that a record number of abstracts were submitted for its 29th Annual Scientific Meeting and Education Day which will be held in Houston this year, with 1329 submissions representing over a 10% increase from 2024. Of note, the number of neurosurgical abstracts increased from 47 submissions to 127.
The scientific co-chairs, Howard Colman, Michelle Monje, Erik Sulman and Humsa Venkatesh, have organized a broad and varied program that includes keynote presentations from Amol Ghia, Douglas Hanahan, and Crystal Mackall. Martin van den Bent will deliver the Victor Levin Lecture and Michelle Monje will present the Abhijit Guha Lecture co-sponsored by SNO and the Section on Tumors. Immediately preceding the main meeting will be SNO’s Education Day, which this year will address the molecular classification of brain tumors and its role in therapy.
The Conference on CNS Metastases, co-sponsored by SNO and ASCO, was held in Denver August 8-10, 2024. Topics addressed include basic and translational research, as well as a broad range of clinical practice topics including radiation therapy, surgery, chemotherapy, targeted therapy/immunotherapy, multimodality therapy and clinical trials. SNO expected record attendance at this event, which sought to leverage multi-sector collaborations to disrupt barriers and streamline therapeutic advances for patients with CNS metastases.
The three titles in the Neuro-Oncology publishing enterprise are thriving and continue to deliver education of the highest quality to multidisciplinary neuro-oncology professionals around the world. The Impact Factor (IF) for SNO’s flagship journal, Neuro-Oncology, has risen from 15.9 to a record-high 16.4 in the newly released Journal Citation Reports™. Given the recent changes during this reporting period in how the IF is calculated – resulting in many journals seeing a decrease this year – this is a remarkable achievement. SNO congratulates editor-in-chief Susan Chang and the past and present editorial teams for their outstanding work, which now sees Neuro-Oncology ranked 4th out of 277 Clinical Neurology titles and 15th out of 322 titles in the Oncology category.
Neuro-Oncology’s sister title, Neuro-Oncology Advances, published in partnership with the European Association of Neuro-Oncology (EANO), also saw a positive IF increase, rising from 3.5 to 3.7. SNO is indebted to founding editor-in-chief Gelareh Zadeh and her entire editorial team for this significant accomplishment, which is especially noteworthy given that NOA is only in its 4th year of publication!
Neuro-Oncology Practice, also published in partnership with EANO, was assigned a very respectable IF score of 2.4. Importantly, the journal’s SCOPUS CiteScore increased to 5.3 (up from 4.9). Neuro-Oncology Practice provides an important platform for the dissemination of applied and practical education in the field, and editor-in-chief Martin Taphoorn and his editorial team are to be commended for their strong work.
Together with our publishing partners, Oxford University Press and EANO, SNO continues to explore exciting new opportunities to expand our publishing enterprise and deliver more education dedicated to advancing the care, research and treatment of adults, children and adolescents with brain tumors.
In closing, we would like to acknowledge the dedication of our members who are on the front lines of research and clinical care. It is thanks to their resilience, creativity and collaborative spirit, we are confident we are making progress to improve outcomes for patients with neurological malignancies.